These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 16167056)
41. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia. Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244 [TBL] [Abstract][Full Text] [Related]
42. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance. Pytel D; Wysocki T; Majsterek I Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383 [TBL] [Abstract][Full Text] [Related]
43. Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission. Pavlu J; Andreasson C; Chuah C; Kaeda J; Goldman JM; Apperley JF; Marin D Br J Haematol; 2007 Jun; 137(5):423-8. PubMed ID: 17428238 [TBL] [Abstract][Full Text] [Related]
44. EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells. Saliba J; Deleuze-Masquéfa C; Iskandarani A; El Eit R; Hmadi R; Mahon FX; Bazarbachi A; Bonnet PA; Nasr R Anticancer Drugs; 2014 Jul; 25(6):624-32. PubMed ID: 24463483 [TBL] [Abstract][Full Text] [Related]
45. Simvastatin enhances the efficacy of nilotinib in chronic myeloid leukaemia by post-translational modification and drug transporter modulation. Asari K; Sun WT; Kok ZH; Lam YH; Ng BL; Saunders V; White DL; Chuah C; Xiang W Anticancer Drugs; 2021 Jun; 32(5):526-536. PubMed ID: 33587350 [TBL] [Abstract][Full Text] [Related]
46. Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavenger for inducing cytotoxicity in imatinib resistant cells. Acharya S; Sahoo SK J Colloid Interface Sci; 2016 Apr; 467():180-191. PubMed ID: 26802277 [TBL] [Abstract][Full Text] [Related]
47. STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Kiper HD; Tezcanli Kaymaz B; Gokbulut AA; Selvi N; Avci CB; Kosova B; Iskender G; Yandim MK; Gunduz C; Sahin F; Baran Y; Saydam G Biomed Pharmacother; 2013 Jul; 67(6):527-32. PubMed ID: 23725755 [TBL] [Abstract][Full Text] [Related]
48. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129 [TBL] [Abstract][Full Text] [Related]
49. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Kimura S; Kuroda J; Segawa H; Sato K; Nogawa M; Yuasa T; Ottmann OG; Maekawa T Int J Hematol; 2004 Jan; 79(1):37-43. PubMed ID: 14979476 [TBL] [Abstract][Full Text] [Related]
51. The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells. Mansouri M; Mirzaei SA; Lage H; Mousavi SS; Elahian F Biochimie; 2014 Apr; 99():71-6. PubMed ID: 24287290 [TBL] [Abstract][Full Text] [Related]
52. The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation. Xie F; Li P; Gong J; Zhang J; Ma J Biochem Biophys Res Commun; 2015 Nov; 467(4):664-9. PubMed ID: 26498526 [TBL] [Abstract][Full Text] [Related]
53. Targeting of Mevalonate-Isoprenoid Pathway in Acute Myeloid Leukemia Cells by Bisphosphonate Drugs. Chiarella E; Nisticò C; Di Vito A; Morrone HL; Mesuraca M Biomedicines; 2022 May; 10(5):. PubMed ID: 35625883 [TBL] [Abstract][Full Text] [Related]
54. The role of cholesterol metabolism in leukemia. Zhao L; Zhan H; Jiang X; Li Y; Zeng H Blood Sci; 2019 Aug; 1(1):44-49. PubMed ID: 35402792 [TBL] [Abstract][Full Text] [Related]
55. The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors. Elshafae SM; Kohart NA; Breitbach JT; Hildreth BE; Rosol TJ Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680215 [TBL] [Abstract][Full Text] [Related]